Key result
Long-term antihypertensive therapy reduces cardiovascular events but fails to lower risk to normotensive levels.
Why the study?
Does long-term antihypertensive drug therapy reduce cardiovascular risk to the level of normotensive subjects in hypertensive patients?
Does long-term antihypertensive drug therapy reduce cardiovascular risk to the level of normotensive subjects in hypertensive patients?
Answers are grounded in this paper and cite their sources.
Long-term antihypertensive therapy reduces cardiovascular morbidity and mortality, but does not normalize risk to the level of normotensive individuals, possibly due to irreversible changes, drug adverse effects, or inadequate blood pressure control.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
L. Hansson (1988) conducted a review in Hypertension. Antihypertensive therapy vs. Normotensive subjects was evaluated. Long-term antihypertensive therapy reduces cardiovascular morbidity and mortality, but fails to lower risks in treated hypertensive patients to the level seen in comparable normotensive subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: